Time filter

Source Type

Garcia S.,University Utrecht | Conde C.,Hospital Clinico Universitario Of Santiago Of Compostela Chus
Mediators of Inflammation

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme with a crucial role in the maintenance of genomic stability. In addition to the role of PARP-1 in DNA repair, multiple studies have also demonstrated its involvement in several inflammatory diseases, such as septic shock, asthma, atherosclerosis, and stroke, as well as in cancer. In these diseases, the pharmacological inhibition of PARP-1 has shown a beneficial effect, suggesting that PARP-1 regulates their inflammatory processes. In recent years, we have studied the role of PARP-1 in rheumatoid arthritis, as have other researchers, and the results have shown that PARP-1 has an important function in the development of this disease. This review summarizes current knowledge on the effects of PARP-1 in rheumatoid arthritis. © 2015 Samuel García and Carmen Conde. Source

Orosa B.,Hospital Clinico Universitario Of Santiago Of Compostela Chus | Martinez P.,Hospital Clinico Universitario Of Santiago Of Compostela Chus | Gonzalez A.,Hospital Clinico Universitario Of Santiago Of Compostela Chus | Guede D.,Trabeculae S.A. | And 6 more authors.
Journal of Bone and Mineral Metabolism

Pharmacological inhibition of signaling through lysophosphatidic acid (LPA) receptors reduces bone erosions in an experimental model of arthritis by mechanisms involving reduced osteoclast differentiation and bone resorption and increased differentiation of osteoblasts and bone mineralization. These results led us to hypothesize that LPA receptor inhibition would be beneficial in osteoporosis. Our aim was to test this hypothesis with the LPA receptor antagonist, Ki16425, in ovariectomized mice, a model of postmenopausal osteoporosis. Ovariectomized mice treated with Ki16425 showed bone loss similar to that observed in the controls. Osteoblast markers, Alpl,Bglap and Col1a1, were increased at the mRNA level but no changes were detected in serum. No additional difference was observed in the Ki16425-treated mice relative to the ovariectomized controls with regard to osteoclast function markers or assays of matrix mineralization or osteoclast differentiation. Thus, pharmacological inhibition of LPA receptor was not beneficial for preventing bone loss in ovariectomized mice, indicating that its favorable effect on bone remodeling is less general than hypothesized. © 2014, The Japanese Society for Bone and Mineral Research and Springer Japan. Source

Hernandez-Martin A.,Hospital Infantil Del Nino Jesus | Garcia-Doval I.,Complexo Hospitalario de Pontevedra CHOP | Aranegui B.,Complexo Hospitalario de Pontevedra CHOP | De Unamuno P.,Complejo Hospitalario de Salamanca | And 12 more authors.
Journal of the American Academy of Dermatology

Background: Previous reports on the prevalence of autosomal recessive congenital ichthyosis (ARCI) were based on single source data, such as lists of members in a patient association. These sources are likely to be incomplete. Objectives: We sought to describe the prevalence of ARCI. Methods: We obtained data from 3 incomplete sources (dermatology departments, a genetic testing laboratory, and the Spanish ichthyosis association) and combined them using the capture-recapture method. Results: We identified 144 living patients with ARCI. Of these, 62.5% had classic lamellar ichthyosis and 30.6% had congenital ichthyosiform erythroderma. The age distribution included fewer elderly patients than expected. The prevalence of ARCI in patients younger than 10 years, the best estimate as less subject to bias, was 16.2 cases per million inhabitants (95% confidence interval 13.3-23.0). According to the capture-recapture model, 71% of the patients were not being followed up in reference units, 92% did not have a genetic diagnosis, and 78% were not members of the ichthyosis association. Limitations: The prevalence of ARCI in Spain and findings related to the Spanish health care system might not be generalizable to other countries. Conclusions: The prevalence of ARCI is higher than previously reported. Many patients are not being followed up in reference units, do not have a genetic diagnosis, and are not members of a patient association, indicating room for improvement in their care. Data suggesting a reduced number of older patients might imply a shorter life expectancy and this requires further study. © 2011 by the American Academy of Dermatology, Inc. Source

Discover hidden collaborations